reports
BB Biotech AG: 1 director
A director at BB Biotech AG bought 1,000 shares at 41.450CHF and the significance rating of the trade was 54/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly ...
EQS-News: BB Biotech presents solid first-quarter results; biotech sto...
EQS-News: BB BIOTECH AG / Key word(s): Interim Report BB Biotech presents solid first-quarter results; biotech stock market impacted by shifting views on interest rates 26.04.2024 / 07:00 CET/CEST The issuer is solely responsible for the content of this announcement. Media release as at April 26, 2024 Portfolio of BB Biotech AG as at March 31, 2024 BB Biotech presents solid first-quarter results; biotech stock market impacted by shifting views on interest rates Investor sentiment in the biotech space continues to be shaped by the general interest rate environment. Biot...
EQS-News: BB Biotech mit solidem Quartalsergebnis, Biotechkapitalmarkt...
EQS-News: BB BIOTECH AG / Schlagwort(e): Zwischenbericht BB Biotech mit solidem Quartalsergebnis, Biotechkapitalmarkt von Zinserwartungen geprägt 26.04.2024 / 07:00 CET/CEST Für den Inhalt der Mitteilung ist der Emittent / Herausgeber verantwortlich. Medienmitteilung vom 26. April 2024 Portfolio der BB Biotech AG per 31. März 2024 BB Biotech mit solidem Quartalsergebnis, Biotechkapitalmarkt von Zinserwartungen geprägt Das Zinsumfeld bestimmt weiterhin massgeblich die Stimmung der Biotechinvestoren. Die Aktienkurse entwickelten sich zu Beginn des Jahres vielversprechend...
EQS-News: Shareholders at BB Biotech AG’s AGM vote in favor of all pro...
EQS-News: BB BIOTECH AG / Key word(s): AGM/EGM/Dividend Shareholders at BB Biotech AG’s AGM vote in favor of all proposals and approve the dividend of CHF 2.00 per share 21.03.2024 / 18:00 CET/CEST The issuer is solely responsible for the content of this announcement. Media release of March 21, 2024 Shareholders at BB Biotech AG’s AGM vote in favor of all proposals and approve the dividend of CHF 2.00 per share All proposals of BB Biotech AG's Board of Directors were approved by BB Biotech AG's shareholders at its Annual General Meeting held today. Shareholders voted ...
EQS-News: Die Generalversammlung der BB Biotech AG stimmt allen Anträg...
EQS-News: BB BIOTECH AG / Schlagwort(e): Hauptversammlung/Dividende Die Generalversammlung der BB Biotech AG stimmt allen Anträgen zu und genehmigt die Dividende von CHF 2.00 pro Aktie 21.03.2024 / 18:00 CET/CEST Für den Inhalt der Mitteilung ist der Emittent / Herausgeber verantwortlich. Medienmitteilung vom 21. März 2024 Die Generalversammlung der BB Biotech AG stimmt allen Anträgen zu und genehmigt die Dividende von CHF 2.00 pro Aktie An der ordentlichen Generalversammlung der BB Biotech AG von heute haben die Aktionäre sämtliche Anträge des Verwaltungsrats angenomm...
EQS-News: Investor interest returns – dividend yield remains high for ...
EQS-News: BB BIOTECH AG / Key word(s): Dividend Investor interest returns – dividend yield remains high for 2024 14.02.2024 / 07:00 CET/CEST The issuer is solely responsible for the content of this announcement. Release as at February 14, 2024Investor interest returns – dividend yield remains high for 2024 After a difficult 2023 stock market year, above all due to higher interest rates, the capital markets are now once again looking at biotech companies with interest. The prospect of falling interest rates has led to a rethink. While the majority of investors favor large...
EQS-News: Anlegerinteresse kehrt zurück – Unverändert hohe Dividendenr...
EQS-News: BB BIOTECH AG / Schlagwort(e): Dividende Anlegerinteresse kehrt zurück – Unverändert hohe Dividendenrendite im 2024 14.02.2024 / 07:00 CET/CEST Für den Inhalt der Mitteilung ist der Emittent / Herausgeber verantwortlich. Mitteilung vom 14. Februar 2024Anlegerinteresse kehrt zurück – Unverändert hohe Dividendenrendite im 2024 Nach einem schwierigen Börsenjahr 2023, dessen Hauptursache die steigenden Zinsen waren, haben die Kapitalmärkte inzwischen wieder Gefallen an Biotechunternehmen gefunden. Die Aussicht auf sinkende Zinsen hat zu einem Umdenken geführt. Währ...
- Fehmi Ben Naamane
AC ACCOR SA
EQNR EQUINOR ASA
GALP GALP ENERGIA SGPS SA CLASS B
ALFOC FOCUS HOME INTERACTIVE SA
OSE OSE IMMUNOTHERAPEUTICS SA
WTB WHITBREAD PLC
BIO BB BIOTECH AG
ENI ENI S.P.A.
REP REPSOL SA
MAREL MAREL HF.
AIXA AIXTRON SE
SHOT SCANDIC HOTELS GROUP
ARG ARGAN SA
MEL MELIA HOTELS INTERNATIONAL S.A.
NHH NH HOTEL GROUP SA
BP. BP P.L.C.
IHG INTERCONTINENTAL HOTELS GROUP PLC
SHEL SHELL PLC
DEME DEME GROUP NV
- Martial Descoutures
- Oussema Denguir
BB Biotech AG : The holding ends the year on a positive note
>A positive Q4 but not enough to improve the 2023 performance - This morning, BB Biotech published its Q4 2023 results. The share price gained 7.1% in € and 3.4% in CHF over the quarter. Over the period, NAV of the portfolio gained +5% in CHF and 14.2% in $ whereas the benchmark NBI (Nasdaq Biotechnology Index) gained around 3% over the last quarter of the year. This results in a net gain of CHF 109m over the period (vs a loss of CHF 35m in Q4 2022). However, the...
- Fehmi Ben Naamane
AC ACCOR SA
EQNR EQUINOR ASA
GALP GALP ENERGIA SGPS SA CLASS B
ALFOC FOCUS HOME INTERACTIVE SA
OSE OSE IMMUNOTHERAPEUTICS SA
WTB WHITBREAD PLC
BIO BB BIOTECH AG
ENI ENI S.P.A.
REP REPSOL SA
MAREL MAREL HF.
AIXA AIXTRON SE
SHOT SCANDIC HOTELS GROUP
ARG ARGAN SA
MEL MELIA HOTELS INTERNATIONAL S.A.
NHH NH HOTEL GROUP SA
BP. BP P.L.C.
IHG INTERCONTINENTAL HOTELS GROUP PLC
SHEL SHELL PLC
DEME DEME GROUP NV
- Martial Descoutures
- Oussema Denguir
BB Biotech AG : La holding finit l’année sur note positive
>Un T4 positif mais pas assez pour redresser la performance 2023 - BB Biotech publie ce matin ses résultats du T4 2023. Le titre de la holding a gagné 7.1% en € et 3.4% en CHF sur le trimestre. Durant la même période, la NAV du portefeuille s’est quant à elle appréciée de 5% en CHF et de 14.2% en $ tandis que son indice de référence le NBI (Nasdaq Biotechnology Index) a gagné environ 3% sur le dernier trimestre de l’année. Il en résulte gain net de 106 MCHF sur la pér...
EQS-News: BB Biotech AG: Jahresendrally des Biotechsektors durch M&A-A...
EQS-News: BB BIOTECH AG / Schlagwort(e): Jahresergebnis/Dividende BB Biotech AG: Jahresendrally des Biotechsektors durch M&A-Aktivitäten und Zinswende beflügelt 19.01.2024 / 07:00 CET/CEST Für den Inhalt der Mitteilung ist der Emittent / Herausgeber verantwortlich. Medienmitteilung vom 19. Januar 2024 Portfolio der BB Biotech AG per 31. Dezember 2023 Jahresendrally des Biotechsektors durch M&A-Aktivitäten und Zinswende beflügelt Die globalen Aktienmärkte entwickelten sich 2023 besser als von vielen Marktteilnehmern erwartet. Die US-Notenbank verlangsamte Anfang 2023 da...
EQS-News: BB Biotech AG: End of year biotech equity market rally – M&A...
EQS-News: BB BIOTECH AG / Key word(s): Annual Results/Dividend BB Biotech AG: End of year biotech equity market rally – M&A and end of rate hike cycle 19.01.2024 / 07:00 CET/CEST The issuer is solely responsible for the content of this announcement. Media release as at January 19, 2024 Portfolio of BB Biotech AG as at December 31, 2023 End of year biotech equity market rally – M&A and end of rate hike cycle In 2023, global equity performed better than anticipated by many. The US central bank moderated and then paused interest rate hikes. These developments resulted in ...
- Pedro Fonseca
BB Biotech - A cutting-edge sector and a high dividend
BB Biotech (BION) offers investors exposure to the innovative, rapidly expanding biotech sector. BION is the largest biotech investor among its investment company peers. It invests in high-quality biotech assets that target substantial market opportunities. BION’s managers are optimistic about the outlook for the sector. They believe sentiment towards the sector should improve as interest rates peak and begin to decline. Meanwhile, they expect to see ongoing fundamental progress by portfolio hol...
- Emmanuel Matot
- Fehmi Ben Naamane
- Marc Lavaud
ALFOC FOCUS HOME INTERACTIVE SA
BFIT BASIC-FIT NV
VAC PIERRE & VACANCES SA
WTB WHITBREAD PLC
FLY SOCIETE FONCIERE LYONNAISE SA
BIO BB BIOTECH AG
STF STEF
BLC BASTIDE LE CONFORT MEDICAL SA
SRP SRP GROUPE SA
GBT GUERBET SA
SAVE SAVENCIA SA
ROYAL VOPAK NV
SHOT SCANDIC HOTELS GROUP
A3TV ATRESMEDIA CORPORACION DE MEDIOS DE COMUNICACION SA
INSD VERIMATRIX SA
LFDE LA FRANCAISE DE L'ENERGIE SA
MEL MELIA HOTELS INTERNATIONAL S.A.
NHH NH HOTEL GROUP SA
TKO TIKEHAU CAPITAL SCA
DUE DURR AG
B4B METRO AG
RBO ROCHE BOBOIS INTERNATIONAL SAS
IHG INTERCONTINENTAL HOTELS GROUP PLC
VRLA VERALLIA SAS
TE TECHNIP ENERGIES NV
ALLFG ALLFUNDS (UK) LTD
STM STABILUS SE
- Emmanuel Matot
- Fehmi Ben Naamane
- Marc Lavaud
ALFOC FOCUS HOME INTERACTIVE SA
BFIT BASIC-FIT NV
VAC PIERRE & VACANCES SA
WTB WHITBREAD PLC
FLY SOCIETE FONCIERE LYONNAISE SA
BIO BB BIOTECH AG
STF STEF
BLC BASTIDE LE CONFORT MEDICAL SA
SRP SRP GROUPE SA
SAVE SAVENCIA SA
ROYAL VOPAK NV
SHOT SCANDIC HOTELS GROUP
A3TV ATRESMEDIA CORPORACION DE MEDIOS DE COMUNICACION SA
LFDE LA FRANCAISE DE L'ENERGIE SA
MEL MELIA HOTELS INTERNATIONAL S.A.
NHH NH HOTEL GROUP SA
TKO TIKEHAU CAPITAL SCA
DUE DURR AG
B4B METRO AG
IHG INTERCONTINENTAL HOTELS GROUP PLC
VRLA VERALLIA SAS
TE TECHNIP ENERGIES NV
ALLFG ALLFUNDS (UK) LTD
STM STABILUS SE
- Martial Descoutures
- Oussema Denguir
BB Biotech AG : Macroeconomic strains offset by fundamental newsflow
>Net loss of CHF 48m in Q3 - BB Biotech released its Q3 2023 figures this morning. Unlike previous quarters, the stock’s performance has moved into positive territory, at 5.9% in CHF and 6.3% in €, but remains negative over the first 9 months of the year at -20.8% (dividend included). The portfolio’s NAV was down -2.2% in CHF, -1.2% in € and -4.2% in $, underperforming the Nasdaq Biotech Index which fell by only 2.8% in $ during this period. This resulted in a net lo...
- Martial Descoutures
- Oussema Denguir
BB Biotech AG : Pressions macroéconomiques contrebalancées par le news...
>Une perte nette de 48 MCHF au T3 - BB Biotech communique ce matin ses chiffres du T3 2023. Le rendement du titre, contrairement aux trimestres précédents, ressort en territoire positif à 5.9% en CHF et 6.3% en € mais demeure négative sur les 9 premiers mois de l’année à -20.8% (dividende inclus). La performance de son portefeuille ressort à -2.2% en CHF, -1.2% en € et -4.2% en $ sous-performant le Nasdaq Biotech Index qui n’a lui reculé que de 2.8% en $ sur la pério...
EQS-News: BB BIOTECH AG: Biotech equity markets in flux: the impact of...
EQS-News: BB BIOTECH AG / Key word(s): Interim Report BB BIOTECH AG: Biotech equity markets in flux: the impact of rising bond yields and shifting healthcare policies 20.10.2023 / 07:00 CET/CEST The issuer is solely responsible for the content of this announcement. Media release as at October 20, 2023 Interim report of BB Biotech AG as at September 30, 2023 Biotech equity markets in flux: the impact of rising bond yields and shifting healthcare policies Expectations that the US central bank would soon reverse its monetary policy stance proved to be premature. The rise ...
EQS-News: BB BIOTECH AG: Biotechnologieaktien im Wandel: Die Auswirkun...
EQS-News: BB BIOTECH AG / Schlagwort(e): Zwischenbericht BB BIOTECH AG: Biotechnologieaktien im Wandel: Die Auswirkungen steigender Anleiherenditen und sich ändernder Gesundheitspolitik 20.10.2023 / 07:00 CET/CEST Für den Inhalt der Mitteilung ist der Emittent / Herausgeber verantwortlich. Medienmitteilung vom 20. Oktober 2023 Zwischenbericht der BB Biotech AG per 30. September 2023 Biotechnologieaktien im Wandel: Die Auswirkungen steigender Anleiherenditen und sich ändernder Gesundheitspolitik Erwartungen über eine baldige Zinswende in den USA erwiesen sich als verfrü...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.